LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

LLY

1,098.63

-3.51%↓

JNJ

227.95

-1.23%↓

ABBV

217.5

-0.26%↓

UNH

380.35

-1.52%↓

MRK

118.68

-1.44%↓

Kodu・Aktsiate loetelu・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Avatud

SektorTervishoid

17.77 -1.93

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.63

Max

18.62

Põhinäitajad
By Trading Economics
Sissetulek	-607K -51M
Müük	-28M 100M
Aktsiakasum	-0.46
Kasumimarginaal	-51.215
Töötajad	1,784
EBITDA	4.1M -44M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+73.35% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-308M 2.1B
Eelmine avamishind	19.7
Eelmine sulgemishind	17.77

Uudiste sentiment

By Acuity

30%

70%

70 / 344 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. mai 2026, 22:47 UTC

Tulu

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28. mai 2026, 20:45 UTC

Tulu

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28. mai 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28. mai 2026, 23:39 UTC

Market Talk

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28. mai 2026, 23:31 UTC

Market Talk

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28. mai 2026, 23:17 UTC

Market Talk

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28. mai 2026, 23:02 UTC

Market Talk

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28. mai 2026, 22:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. mai 2026, 22:41 UTC

Market Talk

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28. mai 2026, 22:37 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

M&A-Related Insurance Payments In North America Rise -- Market Talk

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28. mai 2026, 22:04 UTC

Omandamised, ülevõtmised, äriostud

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28. mai 2026, 21:12 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28. mai 2026, 21:00 UTC

Tulu

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28. mai 2026, 20:57 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:55 UTC

Tulu

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28. mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

28. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

28. mai 2026, 20:48 UTC

Kuumad aktsiad

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28. mai 2026, 20:34 UTC

Tulu

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28. mai 2026, 20:31 UTC

Tulu

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28. mai 2026, 20:28 UTC

Tulu

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28. mai 2026, 20:26 UTC

Tulu

Dell Stock Soars on Blowout Earnings -- Barrons.com

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Membership Fees $1.37B

28. mai 2026, 20:20 UTC

Tulu

Costco 3Q Net Sales $69.15B

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28. mai 2026, 20:19 UTC

Tulu

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28. mai 2026, 20:17 UTC

Tulu

Costco 3Q Same-Store Sales Up 9.8% >COST

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

73.35% tõus

12 kuu keskmine prognoos

Keskmine 32.4 USD 73.35%

Kõrge 44 USD

Madal 21.6 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Zai Lab Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

70 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.